Vor Biopharma Inc. VOR
19.56 USD -0.42 (-2.10%)
At closeNov 11, 2026, 4:48 AM EST
19.15 -0.41 -2.10%
Pre-market · Nov 11, 4:48 AM ET
19.26 Day range 20.23
6.50 52-week range 26.00
- YTD
- +49.54%
- 1 year
- +98.78%
- Market cap
- 1.20B
- EPS (ttm)
- 300.56
- Shares out
- 61.43M
- P/E ratio
- 0.07
- Forward P/E
- -5.85
- YTD return
- +49.54%
- 1-year return
- +98.78%
- Volume
- 405.78K
- Avg volume
- 945.35K
- Open
- 19.75
- Previous close
- 19.98
- Day's range
- 19.26 – 20.23
- 52-week range
- 6.50 – 26.00
- Beta
- 1.83
- Analysts
- Strong Buy
- Price target
- 39.00 (+99.4%)
- Earnings date
- Mar 29, 2027
5D -0.84 (-4.12%)
Key statistics
- Enterprise value
- 748.71M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -46.94M
- Total cash
- 481.55M
- Total debt
- 2.81M
- Return on equity
- 0.00%
- Short % of float
- 14.17%
- 50-day average
- 20.30
- 200-day average
- 17.43
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.00 +99.4% upside
Now 19.56
- Target (low)
- 27.00
- Target (mean)
- 39.00
- Target (high)
- 50.00
Ratings (0m) 10 9 buy · 1 hold · 0 sell
- Strong buy1
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Mar 29, 2027
Expected Mar 29, 2027. Consensus EPS estimate -0.84075.
Financials — quick view
VOR Revenue — quarterly 0
VOR Net income — quarterly -86.73M
VOR EPS — quarterly -1.45
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 29, 2027 | Mar 30, 2027 | -0.92 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | -1.08 | -1.45 | -0.37 | -34.26% |
| Aug 11, 2026 | Jun 30, 2026 | -0.69 | -1.16 | -0.47 | -68.12% |
| May 13, 2026 | Mar 31, 2026 | -0.75 | -0.73 | +0.02 | +2.67% |
| Mar 30, 2026 | Dec 31, 2025 | -1.14 | 44.50 | +45.64 | +4,003.51% |
| Nov 13, 2025 | Sep 30, 2025 | -3.06 | -121.63 | -118.57 | -3,874.84% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | William Blair | init | — | Outperform |
| Aug 12, 2026 | Wedbush | main | Neutral | Neutral |
| May 18, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2026 | Wedbush | main | Neutral | Neutral |
| Apr 15, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Mar 31, 2026 | Wedbush | main | Neutral | Neutral |
About Vor Biopharma Inc.
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vorbio.com
News
Your note
Sign in to keep a note on VOR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANG ROBERT M.D. | Chief Executive Officer | Stock Award(Grant) | Feb 2, 2025 | 921,739 |
| ATTAR EYAL C | Officer | Sale | Feb 12, 2025 | 126,625 |
| CHAKRABORTY TIRTHA | Officer | Stock Award(Grant) | Feb 2, 2025 | 221,272 |
| CHOI HAN WOOK | Chief Financial Officer | Stock Award(Grant) | Feb 2, 2025 | 52,500 |
| MAHATME SANDESH | Chief Financial Officer | Stock Award(Grant) | Jul 8, 2025 | 13,882,800 |
| RA CAPITAL HEALTHCARE FUND,L.P. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Aug 23, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.23% | 5,673,078 | 110.97M | Jun 29, 2026 |
| FMR, LLC | 8.03% | 4,932,149 | 96.47M | Jun 29, 2026 |
| FCPM III Services B.V. | 6.70% | 4,117,354 | 80.54M | Jun 29, 2026 |
| Blackrock Inc. | 5.65% | 3,468,107 | 67.84M | Jun 29, 2026 |
| Venrock Adviser, LLC | 4.95% | 3,041,719 | 59.50M | Jun 29, 2026 |
| State Street Corporation | 4.26% | 2,616,336 | 51.18M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 1,550,885 | 30.34M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 2.28% | 1,399,605 | 27.38M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.07% | 1,270,144 | 24.84M | Aug 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.78% | 1,091,626 | 21.35M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.62% | 996,334 | 19.49M | Sep 29, 2026 |
| Fidelity Capital Trust-Fidelity Stock Selector Small Cap Fund | 1.23% | 758,112 | 14.83M | Aug 30, 2026 |